0000000000242890

AUTHOR

Patrizia Bonadonna

showing 2 related works from this author

SIRM-SIAAIC consensus, an Italian document on management of patients at risk of hypersensitivity reactions to contrast media

2020

Abstract Hypersensitivity reactions (HRs) to contrast media (CM) can be distinguished in immune-mediated (including allergic reactions) and non-immune-mediated reactions, even if clinical manifestations could be similar. Such manifestations range from mild skin eruptions to severe anaphylaxis, making it important for radiologists to know how to identify and manage them. A panel of experts from the Società Italiana di Radiologia Medica e Interventistica (SIRM) and the Società Italiana di Allergologia, Asma e Immunologia Clinica (SIAAIC) provided a consensus document on the management of patients who must undergo radiological investigations with CM. Consensus topics included: the risk stratif…

lcsh:Immunologic diseases. Allergyradiologic contrast media; hypersensitivity reactions; low-osmolar contrast agents; diagnosis; managementmedicine.medical_specialtyAllergyHypersensitivity reactionsReferralImmunologyReviewCulpritRadiologic contrast media03 medical and health sciences0302 clinical medicineDiagnosisHypersensitivity reactionmedicineImmunology and AllergyMedical historyIn patientLow-osmolar contrast agentsIntensive care medicineMolecular Biologybusiness.industryLow-osmolar contrast agentmedicine.diseaseManagement030228 respiratory systemRadiological weaponPremedicationbusinesslcsh:RC581-607AnaphylaxisDiagnosi030215 immunologyClinical and Molecular Allergy
researchProduct

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis w…

2019

Background: The gain-of function mutation KIT D816V plays a central role in the pathogenesis of systemic mastocytosis (SM). Among subtypes of SM, indolent SM (ISM) is the most frequent and is associated with normal/near-normal life expectancy; smoldering SM (SSM) is a subtype with a relatively higher burden of mast cells and may be associated with an increased risk of progression to advanced mastocytosis. However, both ISM and SSM patients may experience severe symptoms associated with mast cell mediator release, such as pruritus, diarrhea, anaphylaxis, and bone pain, which can be severely debilitating and have a profoundly negative impact on quality of life. Symptomatic treatments (eg, ant…

medicine.medical_specialtybusiness.industrySurrogate endpointImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseasePlaceboBiochemistryDouble blindInternal medicineMedicineIn patientSystemic mastocytosismedicine.symptombusinessBone painAsthmaBlood
researchProduct